IntelGenx Technologies Corp.

IGXT

US45822R1014

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 03:04:33 2024-04-26 pm EDT			5-day change	1st Jan Change
0.164 ^USD	-1.61%		-0.61%	+18.75%

Apr. 08	Intelgenx Announces First Parkinson?S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ?Montpark? Clinical Trial	CI
Apr. 05	IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	MT

IntelGenx Technologies : 26 10.45pm MOCK-UP with special characters / * $ % + ` ' ' `

March 15, 2024 at 01:49 pm EDT

26 10.45pm MOCK-UP with special characters / * $ % + ` ' ' `

test body content 26 10.45pm MOCK-UP with special characters / * $ % + ` ' ' `

Attachments

Original Link
Permalink

Disclaimer

IntelGenx Technologies Corp. published this content on 14 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 March 2024 17:48:07 UTC.

Latest news about IntelGenx Technologies Corp.

Intelgenx Announces First Parkinson?S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ?Montpark? Clinical Trial	Apr. 08	CI
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	Apr. 05	MT
IntelGenx Corp. Updates Status of Buprenorphine Buccal Film ANDA	Apr. 05	CI
IntelGenx Technologies Narrows Q4 Loss, Revenue Rises	Mar. 21	MT
Transcript : IntelGenx Technologies Corp., Q4 2023 Earnings Call, Mar 21, 2024	Mar. 21
IntelGenx Technologies Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
IntelGenx Subsidiary Signs Third Amended, Restated Loan Agreement With atai Life Sciences	Mar. 11	MT
IntelGenx Brief: Entering Into a Third Amended and Restated Loan Agreement With atai Life Sciences	Mar. 11	MT
IntelGenx Technologies Corp. announced that it expects to receive $2 million in funding	Mar. 07	CI
IntelGenx Brief: Launching Regulation A Offering of Up to 2 Million shares In Series A Convertible Cumulative Preferred Stock, Par Value $0.00001 Per Share, at an Offering Price of $10.00 Each, For a Max Offering amount of $20 Million	Feb. 20	MT
IntelGenx Technologies Corp. announced that it expects to receive $20 million in funding	Feb. 13	CI
IntelGenx Technologies Corp. Announces Positive Results from Proof-Of-Concept Study to Assess the Palatability, Owner-Perceived Acceptability, and Ease of Repeated Administration of Intelgenx?s VetaFilm® Platform in Healthy Dogs and Cats	Feb. 05	CI
IntelGenx, Covenant Animal Health Partners Unit Sign Development, License Pacts for VetaFilm	Dec. 18	MT
IntelGenx Corp. Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm	Dec. 18	CI
IntelGenx Brief: Announcing New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm	Dec. 18	MT
IntelGenx Technologies Corp. announced that it has received CAD 1.01451 million in funding from ATAI Life Sciences AG	Dec. 04	CI
IntelGenx Technologies Corp. Announces Changes to its Board of Directors	Dec. 04	CI
IntelGenx Announcing Shareholder Approval of Financing Transactions	Nov. 28	MT
IntelGenx Brief: Announcing Shareholder Approval of Financing Transactions	Nov. 28	MT
IntelGenx Receives OK to Conduct Montelukast VersaFilm Phase 2 Clinical Trial in Patients with Parkinson's Disease	Nov. 14	MT
IntelGenx Corp. Receives Approval to Conduct 'Montpark' Montelukast Versafilm Phase 2 Clinical Trial in Patients with Parkinson's Disease	Nov. 14	CI
Transcript : IntelGenx Technologies Corp., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
IntelGenx Technologies Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
IntelGenx Announced Co-development and Commercialization of Cannabinoid-Infused VersaFilm Products with Tilray	Nov. 06	MT
IntelGenx Brief: Announciing Co-development and Commercialization of Cannabinoid-Infused VersaFilm Products with Tilray	Nov. 06	MT

Chart IntelGenx Technologies Corp.

Duration

Period

More charts

Company Profile

IntelGenx Technologies Corp. is a Canada-based drug delivery company. The Company provides single-site, end-to-end contract development and manufacturing services of oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle. The Companyâs film technologies, including VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, allows for pharmaceutical products that address unmet medical needs. It provides comprehensive pharmaceuticals services to pharmaceutical partners, including research and development (R&D), analytical method development, clinical monitoring, IP and regulatory services. Its manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. Its product portfolio includes Migraine (Rizatriptan), Erectile Dysfunction (Tadalafil), Schizophrenia (Lozapine), Neurodegenerative, Opioid Dependence (Buprenorphine / Naloxone) and others.

Sector

Pharmaceuticals

Calendar

2024-05-07 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.164

Average target price

Consensus

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
INTELGENX TECHNOLOGIES CORP.	+18.75%	28.64M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.62%	43.34B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B
SANDOZ GROUP AG	+10.86%	14.09B
CIPLA LIMITED	+13.07%	13.64B
ZYDUS LIFESCIENCES LIMITED	+37.46%	11.43B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B

Generic Pharmaceuticals

IntelGenx Technologies Corp.

Equities

IGXT

US45822R1014

Pharmaceuticals

IntelGenx Technologies : 26 10.45pm MOCK-UP with special characters / * $ % + ` ' ' `

Latest news about IntelGenx Technologies Corp.

Chart IntelGenx Technologies Corp.

Company Profile

Income Statement Evolution

Analysts' Consensus

Sector Generic Pharmaceuticals